Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells
Sara Proietti
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorAlessandra Cucina
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorGabriella Dobrowolny
IIT, IIT viale Regina Elena 291, Rome, Italy
Section of Histology and Medical Embryology, Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Rome, Italy
Search for more papers by this authorFabrizio D'Anselmi
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorSimona Dinicola
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorMaria Grazia Masiello
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Department of Clinical and Molecular Medicine, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorAlessia Pasqualato
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorAlessandro Palombo
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorVeronica Morini
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorRussel J. Reiter
Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA
Search for more papers by this authorCorresponding Author
Mariano Bizzarri
Department of Experimental Medicine, University “La Sapienza”, Rome, Italy
Address reprint requests to Mariano Bizzarri, 14-16, Via Antonio Scarpa, Roma 00161, Italy.
E-mail: [email protected]
Search for more papers by this authorSara Proietti
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorAlessandra Cucina
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorGabriella Dobrowolny
IIT, IIT viale Regina Elena 291, Rome, Italy
Section of Histology and Medical Embryology, Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Rome, Italy
Search for more papers by this authorFabrizio D'Anselmi
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorSimona Dinicola
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorMaria Grazia Masiello
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Department of Clinical and Molecular Medicine, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorAlessia Pasqualato
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorAlessandro Palombo
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorVeronica Morini
Department of Surgery “P. Valdoni”, “Sapienza” University of Rome, Rome, Italy
Search for more papers by this authorRussel J. Reiter
Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA
Search for more papers by this authorCorresponding Author
Mariano Bizzarri
Department of Experimental Medicine, University “La Sapienza”, Rome, Italy
Address reprint requests to Mariano Bizzarri, 14-16, Via Antonio Scarpa, Roma 00161, Italy.
E-mail: [email protected]
Search for more papers by this authorAbstract
Compelling evidence demonstrated that melatonin increases p53 activity in cancer cells. p53 undergoes acetylation to be stabilized and activated for driving cells destined for apoptosis/growth inhibition. Over-expression of p300 induces p53 acetylation, leading to cell growth arrest by increasing p21 expression. In turn, p53 activation is mainly regulated in the nucleus by MDM2. MDM2 also acts as E3 ubiquitin ligase, promoting the proteasome-dependent p53 degradation. MDM2 entry into the nucleus is finely tuned by two different modulations: the ribosomal protein L11, acts by sequestering MDM2 in the cytosol, whereas the PI3K-AkT-dependent MDM2 phosphorylation is mandatory for MDM2 translocation across the nuclear membrane. In addition, MDM2-dependent targeting of p53 is regulated in a nonlinear fashion by MDM2/MDMX interplay. Melatonin induces both cell growth inhibition and apoptosis in MCF7 breast cancer cells. We previously reported that this effect is associated with reduced MDM2 levels and increased p53 activity. Herein, we demonstrated that melatonin drastically down-regulates MDM2 gene expression and inhibits MDM2 shuttling into the nucleus, given that melatonin increases L11 and inhibits Akt-PI3K-dependent MDM2 phosphorylation. Melatonin induces a 3-fold increase in both MDMX and p300 levels, decreasing simultaneously Sirt1, a specific inhibitor of p300 activity. Consequently, melatonin-treated cells display significantly higher values of both p53 and acetylated p53. Thus, a 15-fold increase in p21 levels was observed in melatonin-treated cancer cells. Our results provide evidence that melatonin enhances p53 acetylation by modulating the MDM2/MDMX/p300 pathway, disclosing new insights for understanding its anticancer effect.
References
- 1Bizzarri M, Proietti S, Cucina A et al. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013; 17: 1483–1496.
- 2Mediavilla MD, Sanchez-Barcelo EJ, Tan DX et al. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 2010; 17: 4462–4481.
- 3Mills E, Wu P, Seely D et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005; 39: 360–366.
- 4Reiter RJ, Tan DX, Manchester LC et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 2007; 52: 11–28.
- 5Proietti S, Cucina A, Reiter RJ et al. Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol Life Sci 2013; 70: 2139–2157.
- 6Mediavilla MD, Cos S, Sánchez-Barceló EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999; 65: 415–420.
- 7Meek DW. The p53 response to DNA damage. DNA Repair 2004; 3: 1049–1056.
- 8Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909–923.
- 9Xirodimas DP, Stephen CW, Lane DP. Co-compartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res 2001; 270: 66–77.
- 10Roth J, Dobbelstein M, Freedman DA et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998; 17: 554–564.
- 11Ito A, Kawaguchi Y, Lai CH et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236–6245.
- 12Tang Y, Zhao W, Chen Y et al. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612–626.
- 13Grossman SR. p300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem 2001; 268: 2773–2778.
- 14Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005; 5: 3–8.
- 15Lohrum MA, Ludwig RL, Kubbutat MH et al. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003; 3: 577–587.
- 16Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98: 11598–11603.
- 17de Rozieres S, Maya R, Oren M et al. The loss of mdm2 induces p53 mediated apoptosis. Oncogene 2000; 19: 1691–1697.
- 18Chène P. Inhibiting the p53–MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102–109.
- 19Yang Y, Ludwig RL, Jensen JP et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547–559.
- 20Li M, Zhang Z, Hill DL et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007; 67: 1988–1996.
- 21Li M, Zhang Z, Hill DL et al. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 2005; 65: 8200–8208.
- 22Cucina A, Proietti S, D'anselmi F et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009; 46: 172–180.
- 23Proietti S, Cucina A, D'anselmi F et al. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 2011; 50: 150–158.
- 24Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10: 1565–1569.
- 25Montes de Oca Luna R, WAGNER DS, LOZANO G. Rescue of early embryonic lethality in MDM2-deficient mice by deletion of p53. Nature 1995; 378: 203–206.
- 26Momand J, Wu HH, Dasgupta G. MDM2–master regulator of the p53 tumor suppressor protein. Gene 2000; 242: 15–29.
- 27Reifenberger G, Liu L, Ichimura K et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736–2739.
- 28Daujat S, Neel H, Piette J. MDM2: life without p53. Trends Genet 2001; 17: 459–464.
- 29Momand J, Zambetti GP, Olson DC et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245.
- 30Wang J, Xiao X, Zhang Y et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012; 53: 77–90.
- 31Zhou BP, Liao Y, Xia W et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3: 973–982.
- 32Vashamanin VA, Androphy EJ. Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53.Pathway. Mol Cell Biol Mar 2004; 24: 2144–2152.
- 33van Ham RCA, van der Houven W, van Oordt G et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15: 5349–5357.
- 34Wade M, Wang YV, Wahl GM. The p53 orchestra: MDM2 and MDMX set the tone. Trends Cell Biol 2010; 20: 299–309.
- 35Stad R, Little NA, Xirodimas DP et al. MDMX stabilizes p53 and MDM2 via two mechanisms. EMBO Rep 2001; 2: 1029–1034.
- 36Jackson MW, Berberich SJ. MDMX protects p53 from MDM2-mediated degradation. Mol Cell Biol 2000; 20: 1001–1007.
- 37Gu J, Kawai H, Nie L et al. Mutual dependence of mdm2 and mdmx in their functional inactivation of p53. J Biol Chem 2002; 277: 19251–19254.
- 38Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci 2007; 120: 371–378.
- 39Toledo F, Krummel KA, Lee CJ et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006; 9: 273–285.
- 40Touqan N, Diggle CP, Verghese ET et al. An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas. BMC Clin Pathol 2013; 13: 32–41.
- 41Giordano A, Avantaggiati ML. p300 and CBP: partners for life and death. J Cell Physiol 1999; 181: 218–230.
10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5 CASPubMedWeb of Science®Google Scholar
- 42Banerjee S, Arif M, Rakshit T et al. Structural features of human histone acetyltransferase p300 and its complex with p53. FEBS Lett 2012; 586: 3793–3798.
- 43Grossman SR, Perez M, Kung AL et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998; 2: 405–415.
- 44Ito A, Lai CH, Zhao X et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20: 1331–1340.
- 45Wang X, Taplick JT, Geva N et al. Inhibition of p53 degradation by mdm2 acetylation. FEBS Lett 2004; 561: 195–201.
- 46Kawai H, Nie L, Wiederschain D et al. Dual role of p300 in the regulation of p53 stability. J Biol Chem 2001; 276: 45928–45932.
- 47Gayther SA, Batley SJ, Linger L et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24: 300–303.
- 48Bouras T, Fu M, Sauve AA et al. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem 2005; 280: 10264–71026.
- 49Tyteca S, Legube G, Trouche D. To die or not to die: A HAT Trick. Mol Cell 2006; 24: 807–812.
- 50van Leeuwen I, Lain S. Sirtuins and p53. Adv Cancer Res 2009; 102: 171–195.
- 51Luo J, Nikolaev AY, Imai S et al. Negative control of p53 by Sir2 alpha promotes cell survival under stress. Cell 2001; 107: 137–148.
- 52Kobet E, Zeng X, Zhu Y et al. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA 2000; 97: 12547–12552.
- 53Yuan ZM, Huang Y, Ishiko T et al. Role for p300 in Stabilization of p53 in the response to DNA Damage. J Biol Chem 1999; 274: 1883–1886.
- 54Harper JW, Adami GR, Wei N et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–816.
- 55Gopalakrishna NL, Chin SF, Ozdag H et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA 2004; 101: 7386–7391.
- 56Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48: 6121–6126.
- 57Vousden KH. Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell 2002; 2: 351–352.